Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This was a descriptive, non-interventional, retrospective cohort study among patients with atherosclerotic cardiovascular disease (ASCVD) and hypercholesterolemia, ASCVD-risk equivalent (ASCVD-RE) or familial hypercholesterolemia (FH) administered inclisiran in a real-world setting in Austria.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Overall Cohort | Adult patients with ASCVD and hypercholesterolemia, ASCVD-RE with hypercholesterolemia, or FH, who were prescribed inclisiran in a real-world setting as per clinical practice and according to the label in Austria. |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of Patients who Received Inclisiran Dose 2 and 3 Within Specified Time Intervals | Time intervals:
| Up to 26 months |
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of Patients Taking Different Concomitant Lipid Lowering Therapy (LLT) at Index Date | Index date was defined as the date of first administration of inclisiran. | Day 1 of Month 6 |
| Percentage of Patients who Received Inclisiran Doses Within Specified Time Intervals |
Not provided
Inclusion Criteria:
ASCVD was defined as previous diagnosis of coronary artery disease (CAD), peripheral artery disease (PAD) or cerebrovascular disease (CVD).
ASCVD-RE was defined as: no previous diagnosis of ASCVD at any time on the patient chart and they met at least one of the following criteria:
Exclusion Criteria:
• None.
Not provided
Not provided
Not provided
Not provided
This was a retrospective, noninterventional cohort study.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Novartis Pharmaceuticals | Novartis Pharmaceuticals | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Novartis | East Hanover | New Jersey | 07936 | United States |
Not provided
Not provided
Not provided
Not provided
Time intervals:
|
| Up to 26 months |
| Gender | Baseline |
| Race | Baseline |
| Smoking Status | Patient smoker status:
| Baseline |
| Physical Activity | Physical activity was classified as intense, light, moderate, or unknown. | Baseline |
| Prescribing Physician Specialty | Baseline |
| Age | Baseline |
| Weight | Baseline |
| Height | Baseline |
| Body Mass Index | Baseline |
| Blood Pressure | Blood pressure: systolic and diastolic. | Baseline |
| Percentage of Male Patients by Age Group | Age groups:
| Baseline |
| Percentage of Female Patients by Age Group | Age groups:
| Baseline |
| Percentage of Patients Categorized by Comorbidities | Baseline |
| Cholesterol | Cholesterol included:
| Baseline |
| Triglycerides | Baseline |
| Apolipoprotein B | Baseline |
| Glycated hemoglobin | Baseline |
| Lipoprotein(a) | Baseline |
| Creatinine | Baseline |
| Alanine Aminotransferase | Baseline |
| Aspartate Aminotransferase | Baseline |
| Alkaline phosphatase | Baseline |
| Percentage of Patients With Procedures | Baseline |
| Percentage of Atherosclerotic Cardiovascular Disease (ASCVD) Patients Categorized by Qualifying Diagnosis | Qualifying diagnoses were coronary artery disease (CAD), peripheral artery disease (PAD), and cerebrovascular disease (CVD). | Baseline |
| Percentage of ASCVD-risk Equivalent Patients Categorized by Qualifying Criteria | Qualifying Criteria:
| Baseline |
| Percentage of Patients Categorized by Lipid Lowering Therapies (LLTs) Prior to Index Date | Index date was defined as the date of first administration of inclisiran. | Up to 6 months pre-index date |
| ID | Term |
|---|---|
| D050197 | Atherosclerosis |
| D006937 | Hypercholesterolemia |
| ID | Term |
|---|---|
| D001161 | Arteriosclerosis |
| D001157 | Arterial Occlusive Diseases |
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
| D006949 | Hyperlipidemias |
| D050171 | Dyslipidemias |
| D052439 | Lipid Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided